A high-throughput cell-based assay pipeline for the preclinical development of bacterial DsbA inhibitors as antivirulence therapeutics

Antibiotics are failing fast, and the development pipeline remains alarmingly dry. New drug research and development is being urged by world health officials, with new antibacterials against multidrug-resistant Gram-negative pathogens as the highest priority. Antivirulence drugs, which inhibit bacte...

Descripción completa

Detalles Bibliográficos
Autores principales: Verderosa, Anthony D., Dhouib, Rabeb, Hong, Yaoqin, Anderson, Taylah K., Heras, Begoña, Totsika, Makrina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7810732/
https://www.ncbi.nlm.nih.gov/pubmed/33452354
http://dx.doi.org/10.1038/s41598-021-81007-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7810732/
https://www.ncbi.nlm.nih.gov/pubmed/33452354
http://dx.doi.org/10.1038/s41598-021-81007-y

Ejemplares similares